Sanofi's semuloparin meets VTE endpoint

Sanofi (Euronext:SAN; NYSE:SNY) said semuloparin met the primary endpoint vs. placebo in the Phase III SAVE-ONCO trial to prevent venous thromboembolism (VTE) in cancer patients undergoing chemotherap...